PharmAust ready to trial monepantel on humans to fight motor neurone disease

PharmAust (ASX: PAA) executive chairman and CEO Dr Roger Aston joins Small Caps to discuss the latest news in relation to its lead drug monepantel (MPL).

The biotechnology company has been focused on repurposing the drug as a treatment for cancer and neurodegenerative diseases. It has now confirmed it is ready to proceed with human trials of MPL on patients with motor neurone disease (MND).

The clinical trial will test the safety and tolerability of the drug and identify any signs that indicate it may be capable of slowing the disease.

Tablets specially designed for the trial were made to current good manufacturing practices (cGMP) and have already been shipped to Sydney and Melbourne.

The trial is being funded with support from FightMND, the largest independent funder of MND research in Australia.

PharmAust also has a medicinal chemistry contracting subsidiary based in Perth called Epichem. Earlier this week, it announced new general manager and business development manager appointments.

Articles:
https://smallcaps.com.au/pharmaust-moves-closer-trials-monepantel-patients-motor-neurone-disease/
https://smallcaps.com.au/pharmaust-appoints-new-general-manager-epichem-subsidiary/

For more information on PharmAust:
https://smallcaps.com.au/stocks/PAA/

-----------------------

Small Caps is Australia's #1 site for market news & information on ASX listed small cap companies.

-----------------------

WEBSITE
https://smallcaps.com.au/

PODCAST
https://smallcaps.com.au/podcast/

SOCIAL MEDIA
Facebook: https://www.facebook.com/SmallCapsASX
Twitter: https://twitter.com/SmallCapsASX
LinkedIn: https://www.linkedin.com/company/small-caps/

NEWSLETTER
https://smallcaps.com.au/subscribe/